Complement C9 Monoclonal Antibody (aE11)

* CHF, excl. 8.1% VAT and shipping costs

Product Description

Product is supplied at 1 mL (100 µL/mL). This antibody reacts with a C9 neoantigen of the terminal complement complex (TCC). Application Notes: Functional Assay - This antibody inhibits platelet activation by antiphospholipid antibody serum. IF - Cryosections of 10 µm were dried, fixed in acetone at 4°C for 10 min, dried and blocked for 20 min with PBSA. Positive control: Mucosa from patients with H. Pylori. C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive. C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointe